Which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of PV?

Ropeginterferon Alfa-2b for the treatment of low-risk patients with polycythemia veraПодробнее

Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosisПодробнее

5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia veraПодробнее

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PVПодробнее

Ropeginterferon alpha-2b as an effective treatment against PVПодробнее

Determining the Potential of Ropeginterferon Alfa-2b in Polycythemia VeraПодробнее

What is the news about ropeginterferon?Подробнее

Current and future therapies for PV: ropeginterferon alfa-2bПодробнее

Should ropeginterferon become SoC for all patients with low-risk PV?Подробнее

Management of PV, the role of interferonПодробнее

Clinical updates on the use of ropeginterferon for polycythemia veraПодробнее

Updates in PV treatment: the efficacy of ropeginterferon alfa-2bПодробнее

Upcoming agents in ET and PVПодробнее

Besremi (Ropeginterferon alfa-2b-njft) injection for Polycythemia Vera (PV)Подробнее

10 facts MPN patients need to know about FDA approval of Ropegylated interferon alpha2b (Besremi).Подробнее

Current approaches and new approvals in MF and PVПодробнее

Ropeginterferon, welcome to the USПодробнее

Long-acting interferon: What is the difference?Подробнее

What’s new for the management of polycythemia vera?Подробнее